| OTC Markets: RGIN
Regenicin, Inc. is a biotechnology company, specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. It intends to help develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. The company's first product, PermaDerm is being developed to be the only tissue-engineered skin prepared from autologous skin cells consisting of both epidermal and dermal layers. The second product is anticipated to be TempaDerm, which uses cells obtained from human donors to allow the development of banks of cryopreserved cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patients such as ulcers. Regenicin was founded on September 6, 2007 and is headquartered in Little Falls, NJ.